

Revision date: 07-Apr-2010

Version: 1.2

Page 1 of 7

IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc **Pfizer Pharmaceuticals Group** 235 East 42nd Street New York, New York 10017 1-212-573-2222

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: pfizer-MSDS@pfizer.com Pfizer Ltd **Ramsgate Road** Sandwich, Kent **CT13 9NJ United Kingdom** +00 44 (0)1304 616161 Emergency telephone number: ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Gabapentin Tablets (Neurontin)

Trade Name:	Neurontin®
Chemical Family:	Mixture
Intended Use:	Pharmaceutical product used as anticonvulsant

2. HAZARDS IDENTIFICATION

Appearance:	White, eliptical, film-coated tablets
Statement of Hazard:	Non-hazardous in accordance with international standards for workplace safety.
Additional Hazard Information: Short Term: Known Clinical Effects: EU Indication of danger:	Dust may cause irritation (based on components) The active ingredient is not acutely toxic. Adverse effects associated with therapeutic use include dizziness, tiredness, swelling, and nausea. Not classified
Note:	This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Gabapentin	60142-96-3	262-076-3	Not Listed	73.0
Corn Starch	9005-25-8	232-679-6	Not Listed	*
Talc (non-asbestiform)	14807-96-6	238-877-9	Not Listed	*
Magnesium stearate	557-04-0	209-150-3	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Poloxamer 407	9003-11-6	Not listed	Not Listed	*
Povidone	9003-39-8	Not listed	Not Listed	*

Material Name: Gabapentin Tablets (Neurontin) Revision date: 07-Apr-2010

Purified water	7732-18-5	231-791-2	Not Listed	*
Candelilla wax	8006-44-8	232-347-0	Not Listed	*
Hydroxypropyl cellulose	9004-64-2	Not listed	Not Listed	*
Additional Information:	* Proprietary Ingredient(s) indicated as hat safety.	zardous have been asse	essed under standards f	or workplace
4. FIRST AID MEASURES				
Eye Contact:	Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.			
Skin Contact:	Remove contaminated clothi or persists, get medical atten		in with soap and water.	If irritation occurs
Ingestion:	Get medical attention. Do no give anything by mouth to an		s directed by medical pe	rsonnel. Never
Inhalation:	Remove to fresh air. If not b	reathing, give artificial re	espiration. Get medical	attention.
5. FIRE FIGHTING MEASURES	3			
Extinguishing Media:	Use carbon dioxide, dry cher	nical, or water spray.		
Hazardous Combustion Products:	Not known			
Fire Fighting Procedures:	Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear. Use caution in approaching fire.			
Fire / Explosion Hazards:	Not applicable			
6. ACCIDENTAL RELEASE M	EASURES			
Health and Safety Precautions:	Personnel involved in clean- Section 8). Minimize exposu		ate personal protective e	equipment (see
Measures for Cleaning / Collecting:	Contain the source of spill if i controls dust generation. A cdry solids. Clean spill area the	damp cloth or a filtered		
Measures for Environmental Protections:	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.			
Additional Consideration for Large Spills:	Non-essential personnel sho situations immediately. Clea			
7. HANDLING AND STORAGE				
General Handling:	If tablets or capsules are crus eyes, skin, and clothing. Rel implement appropriate techn prevent occupational exposu emissions of this material to filtration systems or other equ	eases to the environme ical and procedural was re or environmental rele the atmosphere should	nt should be avoided. R te water and waste dispo ases. Potential points o	eview and osal measures to f process

Material Name: Gabapentin Tablets (Neurontin) Revision date: 07-Apr-2010 Page 3 of 7 Version: 1.2

7. HANDLING AND STORAGE

Storage	Conditions:
Storage	Temperature:

Store in a cool, dry place away from direct sunlight. Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Gabapentin	4000
Pfizer OEL TWA-8 Hr:	1200µg/m³
Corn Starch	
ACGIH Threshold Limit Value (TWA)	10 mg/m³ TWA
Australia TWA	10 mg/m ³
Belgium OEL - TWA	Listed
Bulgaria OEL - TWA	Listed
Czech Republic OEL - TWA	Listed
Greece OEL - TWA	Listed
Ireland OEL - TWAs	Listed
OSHA - Final PELS - TWAs:	15 mg/m ³ total
	5 mg/m ³
Portugal OEL - TWA	Listed
Spain OEL - TWA	Listed
Talc (non-asbestiform)	
ACGIH Threshold Limit Value (TWA)	2 mg/m ³ TWA
ACGIH OELs - Notice of Intended Changes	Listed
Australia TWA	2.5 mg/m ³ containing no asbestos fibers
Austria OEL - MAKs	Listed
Belgium OEL - TWA	Listed
Bulgaria OEL - TWA	Listed
Czech Republic OEL - TWA	Listed
Denmark OEL - TWA	Listed
Estonia OEL - TWA	Listed
Finland OEL - TWA	Listed
Greece OEL - TWA	Listed
Hungary OEL - TWA	Listed
Ireland OEL - TWAs	Listed
Netherlands OEL - TWA OSHA - Final PELs - Table Z-3 Mineral D:	Listed
Poland OEL - TWA	TWA-20 mppcf Listed
Portugal OEL - TWA	Listed
Romania OEL - TWA	Listed
Slovenia OEL - TWA	Listed
Spain OEL - TWA	Listed
Sweden OEL - TWAS	Listed
Sweden OLE - TWAS	Listed
Magnesium stearate	
ACGIH Threshold Limit Value (TWA)	10 mg/m³ TWA
Australia TWA	10 mg/m ³
Belgium OEL - TWA	Listed
Ireland OEL - TWAs	Listed
Lithuania OEL - TWA	Listed

8. EXPOSURE CONTROLS / PERSONAL PROTECTION			
Portugal OEL - TWA	Listed		
Spain OEL - TWA	Listed		
Sweden OEL - TWAs	Listed		
The exposure limit(s) listed for solid con	mponents are only relevant if dust may be generated.		
Analytical Method: Engineering Controls: Environmental Exposure Controls: Personal Protective Equipment:	Analytical method available for gabapentin. Contact Pfizer Inc for further information. Engineering controls should be used as the primary means to control exposures. Refer to specific Member State legislation for requirements under Community environmental legislation. Refer to applicable national standards and regulations in the selection and use of personal		
Hands:	protective equipment (PPE). Not required for the normal use of this product. Wear protective gloves when working with		
Hands.	large quantities.		
Eyes:	Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is possible.		
Skin:	Not required for the normal use of this product. Wear protective clothing when working with large quantities.		
Respiratory protection:	Not required for the normal use of this product. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.		

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Film-coated tablets	Color:	White
Molecular Formula:	Mixture	Molecular Weight:	Mixture

10. STABILITY AND REACTIVITY

Chemical Stability:	Stable under normal conditions of use.
Conditions to Avoid:	None known
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

```
General Information:
```

The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Gabapentin

MouseOralLD50> 5000 mg/kgRatOralLD50> 5000 mg/kgRatIVLD50> 2000 mg/kgMouseIVLD501000-2000 mg/kgRatSubcutaneousLD50> 4000 mg/kg

Povidone

Material Name: Gabapentin Tablets (Neurontin) Revision date: 07-Apr-2010

11. TOXICOLOGICAL INFORMATION

Rat Oral LD50 100 g/kg

Talc (non-asbestiform)

Rat Oral LD50 > 1600 mg/kg

Magnesium stearate

RatOralLD50> 2000 mg/kgRatInhalationLC50> 2000 mg/m³Acute Toxicity Comments:A gre

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Gabapentin

Eye Irritation Rabbit Non-irritating

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Gabapentin

52 Week(s)	Rat O	ral 250 mg/kg/day	NOAEL	Liver, Kidney	
52 Week(s)	Monkey	Oral 250 mg/kg	/day NOAEl	 None identified 	
13 Week(s)	Mouse	Oral 1000 mg/kg	/day NOAEI	L No effects at m	aximum dose

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Gabapentin

Reproductive & Fertility Rat Oral 500 mg/kg/day NOAEL Negative Oral 3000 mg/kg/day Embryo / Fetal Development Mouse NOAEL No effects at maximum dose Embryo / Fetal Development Oral 300 mg/kg/day Developmental toxicity, Not Teratogenic Rat NOAEL Embryo / Fetal Development Rabbit Oral 1500 mg/kg/day NOAEL Not Teratogenic, Maternal Toxicity Peri-/Postnatal Development Rat Oral 500 mg/kg/day NOAEL Negative

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Gabapentin

Bacterial Mutagenicity (Ames)Salmonella , E. coliNegativeIn Vitro Chromosome AberrationHamster Lung CellsNegativeIn Vivo Unscheduled DNA SynthesisRat HepatocyteNegativeIn Vivo Chromosome AberrationHamster Bone MarrowNegative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Gabapentin

2 Year(s) Mouse Oral, in feed 2000 mg/kg/day NOEL Not carcinogenic 2 Year(s) Male Rat Oral, in feed 1000 mg/kg/day NOEL Malignant tumors, Pancreas

Carcinogen Status:	None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below
Povidone IARC:	Group 3
Talc (non-asbestiform) IARC:	Group 3

11. TOXICOLOGICAL INFORMATION

12. ECOLOGICAL INFORMATION		
Environmental Overview:	The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.	
13. DISPOSAL CONSIDER	ATIONS	
Waste Treatment Methods:	Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevan known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prever occupational exposure and environmental release. It is recommended that waste minimize be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.	

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:

Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Gabapentin	
Standard for the Uniform Scheduling	Schedule 4
for Drugs and Poisons:	
EU EINECS/ELINCS List	262-076-3
Corn Starch Inventory - United States TSCA - Sect. 8(b) Australia (AICS):	Listed Listed

Material Name: Gabapentin Tablets (Neurontin) Revision date: 07-Apr-2010 Page 7 of 7 Version: 1.2

5. REGULATORY INFORMATION	-
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-679-6
Poloxamer 407	
Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
alc (non-asbestiform)	
Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
EU EINECS/ELINCS List	238-877-9
Povidone	
Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
urified water	
Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2
andelilla wax	
Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
EU EINECS/ELINCS List	232-347-0
ydroxypropyl cellulose	
Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
lagnesium stearate	
Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
EU EINECS/ELINCS List	209-150-3

16. OTHER INFORMATION

Data Sources:	Pfizer proprietary drug development information. Publicly available toxicity information.
Reasons for Revision:	Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.
Prepared by:	Toxicology and Hazard Communication Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.

End of Safety Data Sheet